乳房植入物疾病取出前后的患者报告结局研究
BACKGROUND: Breast implant illness (BII) after aesthetic breast augmentation remains a poorly defined syndrome encompassing a wide spectrum of symptoms.…
要点
- 乳房植入物疾病涵盖多种症状,取出后11个常见症状域显著持续改善。
- 症状改善在术后30天内即可显现,并维持至30天以上。
- BMI大于30或临床可触及包膜挛缩者术后评分改善更显著。
核心结论
- 乳房植入物取出与特定症状改善在研究对象中呈强关联,改善显著且持续。
主要发现
- 术前平均问卷评分26.19±11.24,术后小于30天为9.49±7.56,大于30天为9.46±7.82,差异P<0.001。
- BMI大于30或临床可触及包膜挛缩者问卷评分改善更明显(P=0.039、0.034)。
- 11个常见症状域在术后30天内改善并维持至30天以上。
临床怎么用
- 对乳房植入物疾病患者,取出及全包膜切除可在术后早期带来症状改善并维持。
- BMI大于30或临床可触及包膜挛缩者可能从取出手术中获得更明显的症状改善。
局限性
- 回顾性单术者研究,BII定义及症状评估基于问卷,机制尚未阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast implant illness (BII) after aesthetic breast augmentation remains a poorly defined syndrome encompassing a wide spectrum of symptoms. While previously published series have observed overall symptomatic improvement after breast implant removal, there is a lack of studies evaluating changes in specific symptoms over time. The purpose of this study was to gain an understanding of symptoms associated with BII, and to evaluate how these symptoms change after removal of breast implants and total capsulectomy (explantation). We hypothesized that patients presenting with BII would experience both immediate and sustained improvement in constitutional symptoms after explantation. METHODS: A retrospective study of all patients who underwent explantation by a single surgeon over 2 years was conducted. Repeated-measures analysis of variance accounting for dependency was used to compare symptoms before and after surgery. Multivariate analyses and linear regression models were used to examine the impact of patient- and implant-related factors on changes in symptoms. RESULTS: Seven hundred fifty patients met inclusion criteria. Mean preoperative survey score (26.19 ± 11.24) was significantly different from mean postoperative survey score at less than 30 days (9.49 ± 7.56) and greater than 30 days (9.46 ± 7.82, P < 0.001). Patients with a BMI greater than 30 or those with clinically detectable contracture on examination showed greater improvement on their survey scores (P = 0.039, 0.034, respectively). CONCLUSIONS: Although BII encompasses a large range of symptoms, subjects in this study demonstrated significant and sustained improvement in 11 common symptom domains. This improvement was demonstrable within the first 30 days postoperatively and was maintained beyond 30 days. The study demonstrated a strong association of explantation and specific symptom improvement within the patient population studied. Future investigation will further elucidate possible biologic phenomena to better characterize the pathophysiology and mechanism of BII.
引用
- Wee CE, Younis J, Isbester K, et al. Understanding Breast Implant Illness, Before and After Explantation: A Patient-Reported Outcomes Study. Ann Plast Surg. 2020. PMID: 32530850. doi:10.1097/SAP.0000000000002446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。